Abstracts tagged "safety and vaccines"

Abstract Number: 946 • 2018 ACR/ARHP Annual Meeting
Short-Term Safety of Fractional-Dose Yellow Fever Vaccination in Autoimmune Rheumatic Diseases and Kinetics of White Blood Cells
Adriana C Tonacio¹, Tatiana N Pedrosa², Julio CR Ferreira Filho², Marilia M Sampaio-Barros², Ricardo Fuller², Michelle Lopes², Eduardo Ferreira Borba², Sandra G Pasoto², Emilly Neves², Clovis A Silva³, Rosa M R Pereira⁴, Percival Sampaio-Barros⁵, Danieli Andrade², Ana CM Ribeiro², Julio CB Moraes⁶, Samuel K Shinjo⁷, Renata Miossi⁸, Hermes Higashino⁹, Silvia Costa⁹, Alberto Duarte¹⁰, Elaine P Leon², Marta Lopes⁹, Nadia E Aikawa² and Eloisa Bonfa¹¹, ¹Infectology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, Brazil, ³Pediatric Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, Brazil, ⁴Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁵Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR., São Paulo, Brazil, ⁶Rheumatology Division, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁷Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, Brazil, ⁸Rheumatology, Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, Brazil, ⁹Infectology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, Brazil, ¹⁰Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, Brazil, ¹¹Rheumatology Division, Hospital das Clinicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Brazil faced a new yellow fever (YFV) outbreak that reached the state of Sao Paulo in December 2016. The fractional dose was used in…
Abstract Number: 1440 • 2017 ACR/ARHP Annual Meeting
The Effectiveness of Zoster Vaccine in RA Patients Subsequently Treated with Tofacitinib
Kevin Winthrop¹, Ann Wouters², Ernest Choy³, Chudy Nduaka⁴, Pinaki Biswas², Lisy Wang⁵, Jennifer Hodge², Irina Lazariciu⁶, Koshika Soma⁵, Christopher F Mojcik², Elie Needle⁷ and William F C Rigby⁸, ¹Oregon Health & Science University, Portland, OR, ²Pfizer Inc, New York, NY, ³CREATE Center, Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom, ⁴Pfizer Inc, Collegeville, PA, ⁵Pfizer Inc, Groton, CT, ⁶QuintilesIMS, Saint-Laurent, QC, Canada, ⁷Pfizer Inc, Pearl River, NY, ⁸Geisel School of Medicine at Dartmouth, Lebanon, NH
Background/Purpose: RA patients (pts) are at increased risk of herpes zoster (HZ), and ACR guidelines recommend vaccination in pts aged ≥50 years prior to starting…
Abstract Number: 1506 • 2016 ACR/ARHP Annual Meeting
One Third of Patients with Established Rheumatoid Arthritis (RA) Are Correctly Vaccinated Against Influenza and Pneumococcus and This Is Increasing: 3 Year Longitudinal Assessment of 776 Patients
Laure Gossec¹, Martin Soubrier², Frantz Foissac³, Anna Molto⁴, Thomas Bardin⁵, Francis Berenbaum⁶, Alain Cantagrel⁷, Marie Hélène Cerato⁸, Gerard H. Chales⁹, Isabelle Chary-Valckenaere¹⁰, Bernard Combe¹¹, Emmanuelle Dernis Labous¹², Liana Euller-Ziegler¹³, Rene-Marc Flipo¹⁴, Philippe Gaudin¹⁵, Melanie Gilson¹⁶, Sandrine Guis¹⁷, Xavier Mariette¹⁸, Gaël Mouterde¹⁹, Sophie Pouplin²⁰, Pascal Richette²¹, Alain Saraux²², Thierry Schaeverbeke²³, Jean Sibilia²⁴, Françoise Fayet²⁵ and Maxime Dougados²⁶, ¹Rheumatology, Pitié Salpêtrière Hospital, Paris, France, ²Rheumatology, Department of Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France, ³COMEDRA working group, Paris, France, ⁴Hopital Cochin, Paris Descartes University, Paris, France, ⁵Hôpital Lariboisière, Paris, France, ⁶Rheumatology dept, APHP St-Antoine hospital, Univ Paris 06, Paris, France, Paris, France, ⁷Purpan Hospital, Toulouse, France, ⁸University Hospital, Toulouse, France, ⁹CHU RENNES, Rennes, France, ¹⁰University Hospital, Nancy, France, ¹¹Lapeyronie Hospital, Montpellier, France, ¹²Le Mans Hospital, Le Mans, France, ¹³Rheumatology, Nice, France, ¹⁴Rheumatology, University Hospital, Lille, France, ¹⁵Rheumatology, Grenoble University Hospital, France, Grenoble, France, ¹⁶Hopital Sud, Grenoble, France, ¹⁷Rheumatology 1, CRMBM-CEMEREM 7339, Aix-Marseille Université, AP-HM, CNRS, Marseilles, France, ¹⁸Rheumatology, Rheumatology department, Bicetre Hospital, Paris-Sud University, Le Kremlin Bicetre, France, ¹⁹Rheumatology Department, Hopital Lapeyronie, Montpellier, France, ²⁰Rheumatology Department & Inserm 905, Department of Rheumatology, Rouen University Hospital & Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen, France, ²¹Rhumatologie, Hôpital Lariboisière, Paris, France, ²²Rheumatology Department, CHU de la Cavale Blanche, Brest Cedex, France, ²³Rheumatology, CHU Bordeaux, Bordeaux, France, ²⁴Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ²⁵Rheumatology, CHU Gabriel-Montpied, Clermont-Ferrand, France, ²⁶Cochin Hospital and Paris 05 University, Paris, France
Background/Purpose: Influenza and pneumococcal vaccinations are recommended in all patients with RA. However, it is well known that a gap exists between recommendations and their…
Abstract Number: 1836 • 2014 ACR/ARHP Annual Meeting
Safety of Zoster Vaccination Administration in Rheumatic Patients on Current Biologic Therapy
Stephen Lindsey¹, Brandi Oufnac² and Holly Walker², ¹Chief Div of Rheumatology, Ochsner Clinic Baton Rouge, Baton Rouge, LA, ²Rheumatology, Ochsner Health Systems, Baton Rouge, LA
Background/Purpose Herpes Zoster (HZ) occurs in 1 in 3 people in the U.S. during their lifetime. The greatest risk factor is age. Immune suppression from…
Abstract Number: 2167 • 2013 ACR/ARHP Annual Meeting
23-Valent Polysaccharide Pneumococcal Vaccine in Juvenile Idiopathic Arthritis Patients: Anti-Tumor Necrosis Factor Therapy Role in Short and Long-Term Immunogenicity
Nadia E. Aikawa¹, Ivan L.A. França², Ana C. M. Ribeiro³, Adriana M. Sallum⁴, Eloisa Bonfa⁵ and Clovis A. Silva⁴, ¹Reumatologia, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ²Division of Infectious Diseases, University of São Paulo, São Paulo, Brazil, ³Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁴Pediatric Rheumatology Unit, University of São Paulo, São Paulo, Brazil, ⁵Rheumatology Division, University of São Paulo, Sao Paulo, Brazil
Background/Purpose: There is no study regarding short and long-term assessments of 23-valent polysaccharide pneumococcal vaccine (PPV23) in juvenile idiopathic arthritis (JIA) under biologic therapy. The objectives…
Abstract Number: L17 • 2013 ACR/ARHP Annual Meeting
Safety and Immunogenicity of Inactivated Varicella-Zoster Virus Vaccine in Adults with Autoimmune Disease
Lawrence McAdam¹, Michael Eberhardson², William Grainger³, Kim Papp⁴, Stephen Hall⁵, Tina Sterling⁶, Jon Stek⁶, Lei Pang⁶, Yanli Zhao⁶, Ivan Chan⁶, Richard Haupt⁶, Janie Parrino⁶ and Jeffrey Silber⁶, ¹Advanced Rheumatology, Infusion and Clinical Research Center, Thousand Oaks, CA, ²Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, ³Neurological Physicians of Arizona, Gilbert, AZ, ⁴K. Papp Clinical Research,, Waterloo, ON, Canada, ⁵Emeritus Research, Malvern, Australia, ⁶Merck & Co., Inc., Whitehouse Station, NJ
Background/Purpose: Patients with autoimmune diseases are often immunocompromised, resulting in higher incidence of HZ than in immunocompetent individuals with significant morbidity and occasional mortality from…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].